Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: initial results from HER2-CR study

Initial results from the prospective HER2-CR registry (NCT06663787) in 37 evaluable patients with long-term CR/PR on anti-HER2 therapy for HER2-positive metastatic breast cancer found that 129 of 142 plasma samples (91%) were negative on Signatera Genome and 30 of 37 patients (81%) were negative at every assessment; all 23 patients without radiographic residual disease remained ctDNA-negative, while persistent positivity was more often accompanied by progression.

ESMO OpenPubMed 43014086DOI 10.1016/j.esmoop.2026.108639